Sinapsos Podcast | Oncology

By Sinapsos PodcastScience Technology Education Courses

Sinapsos Podcast | Oncology episodes

February 18E27 - Histotripsy Boosts Survival in Brain Cancer
E27 | 12 min | Latest | Publication Link
Podcast based on: Duclos, S.; Kaovasia, T.P.; Fox, A.; Cornett, A.; Pandey, A.S.; Xu, Z. First Report of Histotripsy-Induced Survival Benefit in Murine Glioblastomas. Cancers 2026, 18, 622. https://doi.org/10.3390/cancers18040622
Type: Article | Publication date: 13 February 2026

Summary: Histotripsy is a noninvasive soft tissue ablation technique that uses high-pressure ultrasound to generate precise regions of cellular destruction within tumors while sparing surrounding healthy tissue. This study evaluated the survival benefit of a single transcranial histotripsy treatment in glioblastoma-bearing mice using a raster-scanning pattern with varying numbers of histotripsy pulses. Histotripsy resulted in an 18.5% increase in survival compared with untreated controls and was well tolerated with no significant acute or chronic adverse effects. These findings support further investigation of histotripsy as a potential therapeutic approach for brain tumors.

Keywords: glioblastoma; murine model; transcranial histotripsy

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.
12 min
February 18E26 - Advances in Liver Cancer Treatment
E26 | 13 min | Latest | Publication Link
Podcast based on: Morishita, A.; Oura, K.; Tai, H.; Yano, R.; Nakahara, M.; Tadokoro, T.; Fujita, K.; Mimura, S.; Tani, J.; Tatsuta, M.; Himoto, T.; Kobara, H. Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future Perspectives. Cancers 2026, 18, 609. https://doi.org/10.3390/cancers18040609
Type: Review | Publication date: 12 February 2026

Summary: Hepatocellular carcinoma (HCC) arises mostly in chronically diseased livers, so clinicians must manage both an aggressive cancer and a fragile organ simultaneously. This review explains how modern HCC care has evolved into an integrated continuum: from prevention and surveillance to curative options such as resection, ablation, and transplantation, to refined locoregional therapy and immunotherapy-based systemic regimens. We highlight how treatment decisions are tailored according to tumor stage, liver function, portal hypertension, and frailty, and why preserving hepatic reserve is crucial to allow multiple lines of therapy. We also summarize emerging tools such as biomarkers, liquid biopsy, radiomics, and microbiome research that may support more precise treatment selection. Finally, we discuss special populations, safety considerations, and future strategies that combine innovative and traditional approaches to improve survival and quality of life for patients with HCC worldwide. This review aims to guide practical clinical decision-making.

Keywords: hepatocellular carcinoma; cirrhosis; surveillance; Barcelona Clinic Liver Cancer; transarterial chemoembolization; radioembolization; stereotactic body radiotherapy; immune checkpoint inhibitor; tyrosine kinase inhibitor; biomarkers

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.
13 min
February 18E25 - Eribulin s Effect on Breast Cancer Plasticity
E25 | 12 min | Latest | Publication Link
Podcast based on: Bidgood, C.L.; Morera, E.; Jaradi, B.; van Wyngaard, T.; Koikalethu, A.T.; Bock, N.; Agarwal, V.; Redfern, A.D.; Thompson, E.W. Effects of Eribulin on Epithelial–Mesenchymal Plasticity in Patient-Derived Breast Cancer Cultures and Excised Tissues. Cancers 2026, 18, 598. https://doi.org/10.3390/cancers18040598
Type: Article | Publication date: 11 February 2026

Summary: Eribulin is an approved therapy for the treatment of breast cancer which has been shown to reverse the epithelial-to-mesenchymal transition (EMT) and improve the efficacy of standard chemotherapies in cell lines, animal studies, and clinical specimens. Tumour EMT status has also been linked to eribulin efficacy. Based on this, we evaluated the effects of eribulin in patient-derived breast cancer cultures and a triple-negative breast cancer cell line to assess changes to EMT and therapy response. We further identified the induction of epithelial-like characteristics, including E-cadherin expression in a patient-derived HER2+ primary tissue with a predominantly mesenchymal phenotype following longitudinal eribulin exposure. Additionally, we compared EMT marker expression in breast cancers treated with standard-of-care neoadjuvant docetaxel, Adriamycin and cyclophosphamide (TAC) therapy with that observed in the neoadjuvant eribulin clinical trial.

Keywords: breast cancer; eribulin; EMT; chemoresistance

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.
12 min
February 18E24 - ABHD5 in Cancer Research Progress
E24 | 13 min | Latest | Publication Link
Podcast based on: Cai, H.; Chen, H.; Ye, J.; Jin, Z.; Huang, P. Current Research Progress on ABHD5 in Cancers. Cancers 2026, 18, 585. https://doi.org/10.3390/cancers18040585
Type: Review | Publication date: 10 February 2026

Summary: ABHD5 is a key regulator of lipid metabolism, with context-dependent roles in cancer. It interacts with signaling pathways like AMPK/mTOR, AKT, and NF-κB, exerting either tumor-suppressive or oncogenic effects based on the tumor’s ecological and molecular context. This review synthesizes experimental and clinical evidence to clarify its multifaceted functions and explores its potential as a diagnostic marker and therapeutic target, emphasizing the need for precision strategies rather than blunt intervention.

Keywords: ABHD5; lipid metabolism; cancer; pathway

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.
13 min
February 02E23 - Surgery for Mediastinal Paragangliomas 20-Year Review
E23 | 16 min | Latest | Publication Link
Podcast based on: Rotolo, N.; Cerretani, G.; Casagrande, S.; Nardecchia, E.; Asteggiano, E.; Colombo, A.; Filipponi, L.; Piacentino, F.; Ilaria, S.; Fontana, F. Surgical Approaches and Perioperative Outcomes in Mediastinal Paragangliomas: A 20-Year Comprehensive Systematic Review. Cancers 2026, 18, 486. https://doi.org/10.3390/cancers18030486
Type: Systematic Review | Publication date: 01 February 2026

Summary: This study reviews the surgical management of a mediastinal paraganglioma, a rare type of tumor that is often located in the posterior mediastinum and can surround or involve the heart and major blood vessels. Often asymptomatic or with symptoms related to catecholamine secretion, the surgical approach is the treatment of choice, achieving local disease control and long-term outcomes. However, surgical removal poses a high risk of severe bleeding and perioperative complications. By analyzing literature from the last twenty years, we aim to establish a clearer and safer approach for diagnosis and surgery. The findings will help surgeons better plan these complex operations, potentially reducing complications and improving patient care for this uncommon but dangerous condition.

Keywords: mediastinal paraganglioma; surgical resection; cardiopulmonary by-pass; post-operative complications; systematic review

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.
16 min
February 02E22 - SLPI s Role in Prostate Cancer
E22 | 11 min | Latest | Publication Link
Podcast based on: Rosini, D.; Cosi, I.; De Iaco, P.; Sebastianelli, A.; Di Stefano, G.; Serni, S.; Nesi, G.; Notaro, R.; De Angioletti, M. SLPI in Prostate Cancer. Cancers 2026, 18, 487. https://doi.org/10.3390/cancers18030487
Type: Review | Publication date: 01 February 2026

Summary: SLPI is a protein that usually acts as a protective shield for our body’s internal surfaces. Its main jobs are to prevent tissue damage, fight germs, and control inflammation. However, in the context of cancer, SLPI acts like a double-edged sword. While it normally keeps us healthy, many cancers—including lung and breast cancer—hijack this protein to grow and spread more easily. In these cases, high levels of SLPI often signal a more aggressive disease. Interestingly, the opposite happens in some cases, like liver cancer, where more SLPI can be a positive sign. Prostate cancer shows a unique pattern: SLPI protein levels are low in the early stages but rise sharply as the cancer becomes advanced and resistant to treatments. By studying these shifts, scientists can better understand how a tumor behaves, helping doctors predict the disease’s path and develop more effective, personalized treatments for patients.

Keywords: androgen; androgen receptor; biomarker; ETS transcription factors; ETV1; ETV4; transgenic mouse model; prostate cancer; secretory leukocyte protease inhibitor; SLPI

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.
11 min
February 02E21 - PBK Expression and Immune-Activated Colorectal Cancer
E21 | 12 min | Latest | Publication Link
Podcast based on: Sawaguchi, H.; Uehara, T.; Iwaya, M.; Asaka, S.; Nakajima, T.; Komamura, S.; Imamura, S.; Iwaya, Y.; Sugenoya, S.; Kitazawa, M.; Soejima, Y.; Ota, H.; Nagaya, T. The Correlation of PBK Expression with an Immune-Activated Tumor Microenvironment and Outcome in Colorectal Cancer. Cancers 2026, 18, 482. https://doi.org/10.3390/cancers18030482
Type: Article | Publication date: 31 January 2026

Summary: Colorectal cancer shows large differences in patient outcomes, partly because tumors vary in their biological and immune characteristics. Identifying markers that reflect these differences is important for improving prognosis and treatment strategies. PDZ-binding kinase (PBK) is a protein involved in cell division and has been linked to cancer progression, but its clinical significance in colorectal cancer remains unclear. In this study, we examined PBK expression in tumor tissues from patients with colorectal cancer and analyzed its relationship with tumor features, immune cell infiltration, and patient survival. We found that tumors with high PBK expression were associated with a more active immune environment and better clinical outcomes. These findings suggest that PBK expression may help identify colorectal cancer patients with a favorable immune response and prognosis, providing useful information for future research and potential treatment stratification.

Keywords: colorectal cancer; tumor microenvironment; prognosis; immune microenvironment

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.
12 min
February 02E20 - Multi-Targeted TKIs for Advanced Ewing Sarcoma
E20 | 11 min | Latest | Publication Link
Podcast based on: Michelon, I.; do Rêgo Castro, C.E.; Querino Belluco, A.P.; Dacoregio, M.I.; Priantti, J.; Witt, R.G.; Attia, S.; Vilbert, M.; Cavalcante, L. Multi-Targeted TKIs in Patients with Advanced Ewing Sarcoma: A Systematic Review and Single-Arm Meta-Analysis. Cancers 2026, 18, 465. https://doi.org/10.3390/cancers18030465
Type: Systematic Review | Publication date: 30 January 2026

Summary: Ewing sarcoma is a rare and aggressive cancer that often relapses after treatment. There is no clear standard therapy for patients whose disease progresses. Tyrosine kinase inhibitors have recently shown promising results. We reviewed and pooled data from published clinical trials and real-world studies to better evaluate the efficacy and safety of tyrosine kinase inhibitors in relapsed Ewing sarcoma patients. In our pooled analyses of 14 studies, we found an objective response rate of 23% and a disease control rate of 61.1%. Cabozantinib and regorafenib showed the most consistent benefits among drugs available in Western countries. These findings suggest the potential of tyrosine kinase inhibitors in the treatment of such a challenging population.

Keywords: tyrosine kinase inhibitor; Ewing sarcoma; multiply refractory disease; TKI

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.
11 min
February 02E19 - Endometrial Mixed Carcinomas Clinicopathologic Insights
E19 | 13 min | Latest | Publication Link
Podcast based on: Bhardwaj, S.; Saleh, M.; Kinoshita, Y.; Brody, R.; Lukatskaya, O.; Blank, S.V.; Baskovich, B.; Kalir, T. Endometrial Mixed and Mixed-Feature Carcinomas: Small Cohort Clinicopathologic and Molecular Studies. Cancers 2026, 18, 440. https://doi.org/10.3390/cancers18030440
Type: Article | Publication date: 29 January 2026

Summary: Endometrial cancer is a prevalent disease worldwide. There are different kinds of endometrial cancers and their treatment is based on the specific type of cancer—termed the histologic type, and the extent of disease spread—termed stage. The pathology diagnosis of the specific type of endometrial cancer is improving because of our ability to identify specific gene mutations that are unique to the different histologic groups of endometrial cancer. Discovering more about these gene mutations will enable us to design better, more personalized treatment, and avoid having patients try medicines that may not be effective at eliminating their tumor cells. In this current research investigation, we studied a rare sub group of endometrial cancers called mixed carcinomas. There are currently no treatment guidelines for this particular group, and we wanted to learn more about their gene mutations in order to better guide future therapy.

Keywords: mixed endometrial cancer; mixed-feature endometrial cancer; molecular genetics; endometrial cancer

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.
13 min
February 02E18 - Multi-Target Radiotherapy Conformity Index
E18 | 12 min | Latest | Publication Link
Podcast based on: Sang, Y.; Dang, J.; Wu, J.; Wu, Y.; Quan, E.; Dai, J. Generalization of the Conformity Index for Multi-Target Radiotherapy Plans. Cancers 2026, 18, 426. https://doi.org/10.3390/cancers18030426
Type: Article | Publication date: 28 January 2026

Summary: This study proposes a generalized method to calculate the Conformity Index (CI) for multi-target radiotherapy plans (e.g., breast or nasopharyngeal cancer). Standard CI formulas are often distorted in these complex scenarios because they erroneously include dose spillover from adjacent targets. To address this, we redefined the Target Volume (VTV) parameter to mathematically isolate the prescription dose region of each specific target. Validation on clinical plans demonstrated that the new formula effectively eliminates interference from neighboring targets, providing CI values that accurately reflect the true dose conformity. This improved calculation is recommended for the objective evaluation of multi-target radiotherapy plans.

Keywords: radiotherapy planning; generalized conformity index; evaluation; multi-target plans

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.
11 min

About Sinapsos Podcast | Oncology

From the publisher's feed

Zero Fluff. Pure Insight.

Share Sinapsos Podcast | Oncology

Sign up to save your podcasts

Sinapsos Podcast | Oncology

Sinapsos Podcast | Oncology episodes

About Sinapsos Podcast | Oncology